A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485.

about

A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485.

Item

http://www.wikidata.org/entity/Q52641884

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

A novel regimen for relapsed/r ...... lts of phase 1 study NCI 8485.

@en

A novel regimen for relapsed/r ...... lts of phase 1 study NCI 8485.

@nl

type

Item

label

A novel regimen for relapsed/r ...... lts of phase 1 study NCI 8485.

@en

A novel regimen for relapsed/r ...... lts of phase 1 study NCI 8485.

@nl

prefLabel

A novel regimen for relapsed/r ...... lts of phase 1 study NCI 8485.

@en

A novel regimen for relapsed/r ...... lts of phase 1 study NCI 8485.

@nl

P1476

A novel regimen for relapsed/r ...... lts of phase 1 study NCI 8485.

@en

P2093

Alice S Mims

http://www.w3.org/2001/XMLSchema#string

Alison R Walker

http://www.w3.org/2001/XMLSchema#string

Anjali Mishra

http://www.w3.org/2001/XMLSchema#string

Daniel Jones

http://www.w3.org/2001/XMLSchema#string

Gerard Lozanski

http://www.w3.org/2001/XMLSchema#string

James Blachly

http://www.w3.org/2001/XMLSchema#string

Katherine J Walsh

http://www.w3.org/2001/XMLSchema#string

Michael A Caligiuri

http://www.w3.org/2001/XMLSchema#string

Michael R Grever

http://www.w3.org/2001/XMLSchema#string

Ramiro Garzon

http://www.w3.org/2001/XMLSchema#string

P2860

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

Histone deacetylases and cancer: causes and therapies.

Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.

Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations.

Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.

Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia

Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.

The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy

P31

scholarly article

P356

10.3324/HAEMATOL.2017.186890

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-03-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29567781

http://www.w3.org/2001/XMLSchema#string

P932

6058798

http://www.w3.org/2001/XMLSchema#string